SFL CEO awarded Global Fellow in Medicines Development
On 16 July 2020, SFL’s CEO Shayesteh Fürst-Ladani> will be recognized for her contributions to the advancement of Pharmaceutical Medicine by theInternational Federation of Associations of Pharmaceutical Physicians> (IFAPP) and awarded as Global Fellow in Medicines Development (GFMD).
The award acknowledges Shayesteh’s extensive contributions to medicines development over her career, from her prior roles working at Global Pharma companies to her current endeavors as CEO of SFL.
Shayesteh has made significant contributions through strategic advice to many international companies developing highly innovative drugs, devices, IVDs and combination products, as well as in her work advising start-ups for the Swiss Innovation AgencyInnosuisse>, and as a member of the expert panel for the BIOPÔLEDigital Health Hub>.
Shayesteh also leads two not-for-profit Associations as President; theMedtech & Pharma Platform (MPP) Association> to enhance synergies between the pharma and medtech focusing on combined products, and theRare Disease Action Forum >helping to improve access to diagnosis and treatment for patients with rare diseases in Switzerland. She has been very active assessing the impact of legislation, such as the Cell & Tissue Directive, the ATMP Regulation, the Orphan Medicinal Product Regulation, Medical Devices and In vitro Diagnostics Regulations, Drug & Device Combination Products and Personalized Medicine.
The SFL team provides both strategic and operational support for projects covering all lifecycle stages, from regulatory affairs to quality assurance, pharmacovigilance, medical affairs, reimbursement, public affairs and supply chain management, utilizing its unique combination of expertise and a multi-disciplinary approach.